Antisense Therapeutics

Approval granted to restart phase IIa trial of antisense compound in MS patients

Published in Physician Law Weekly, February 8th, 2006

Antisense Therapeutics reported that the Ethics Committee of the University of Essen in Germany has approved the company's application to restart the phase IIa trial of its antisense compound, ATL1102, for patients with relapsing remitting multiple sclerosis.

The University of Essen is the primary trial site for the phase IIa clinical trial. The company now has the requisite approval and regulatory documentation in place to restart the phase IIa trial at this centre.

Patient enrollment and dosing are expected to commence at the University of Essen in February/March 2006. The other eight trial centers will, in turn, be initiated in the coming months....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Physician Law Weekly

Source: Physician Law Weekly (2006-02-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry